If we get it wrong, there is the opportunity for innovation to be deselected out of the country and go into other jurisdictions.
On the confidential business information piece, there was one amendment from the Senate—on living organisms, admittedly—where they required demonstrable need to be the test for the approval of a new living organism. That is a marked departure from the risk-based approach.